Aarkstore - Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015

1
Aarkstore - Antibody Drug Conjugate Insight
Pipeline Assessment, Technology Trend, and
Competitive Landscape, 2015
Category Pharmaceuticals and Healthcare
2
Summary
Antibody-Drug Conjugate Global Market and
Pipeline Outlook, 2015, report provides the
information across the ADCs drug value chain. The
Report provides the marketed and pipeline
scenario of the ADCs. The Report has covered the
264 Antibody-drug conjugates profile which gives
core information of the targets, mechanism of
action, development partner, Technology partner,
monoclonal antibody used, linker used and
cytotoxic drug with the descriptive information
of the technologies. The Report also provides the
assessment of the companys undergone
collaborations for technology and monoclonal
antibody and also gives insights over the
pre-clinical and clinical data. The Report has
also assessed the ADCs on geographical
distribution based on the country and region.
Browse Complete Report http//www.aarkstore.com
/pharmaceuticals-healthcare/106496/antibody-drug-c
onjugate-insight-pipeline-assessment-technology-tr
end-and-competitive-landscape
3
Report Facts

• Antibody-Drug Conjugates (ADCs) are monoclonal
  antibodies (mAbs) attached to biologically active
  drugs by chemical linkers with labile bonds. The
  ongoing research on this therapy will replace the
  chemotherapeutics treatments in the near future
  thereby reducing its toxic side effects. Billions
  of dollars are spent on the chemotherapy
  treatments annually. Different Biotechnology
  companies and Pharma Companies are collaborating
  in all area of ADCs like linker technology,
  antibody production and conjugation process.
  Seattle Geneticss Brentuximab vedotin and
  Roches trastuzumab emtansine are the only ADCs
  approved which have together made USD 523
  millions sales in 2013. There are total 264 ADCs
  in pipeline with 253 ADCS are developing only for
  Oncology indications. Pipeline is very rich with
  four potential drugs in Phase III stage out of
  which Kadcyla and Adcetris are undergoing
  clinical studies for different conditions.

4
Scope

•   A snapshot of the global Antibody-Drug
  Conjugate market scenario, market trends
  drivers, manacles of Antibody-Drug Conjugate. 
  A review of the marketed Antibody-Drug Conjugate
  products and marketing status  Coverage of
  global antibody-drug conjugate therapies under
  development across the globe covering
  territories  Competitive landscape of
  investigational products for key players and key
  therapy areas.  The Antibody-Drug Conjugate
  report covers the product description, stage of
  development, licensors collaborators,
  Development partner and Technology information

5
Reasons to buy

• Complete Market and Pipeline intelligence and
  complete understanding over therapeutics
  development for Antibody-Drug Conjugate  Devise
  corrective measures for pipeline projects by
  understanding Therapy area specific therapies 
  Developing strategic initiatives to support your
  Antibody-Drug Conjugate development
  activities.  Optimize your portfolio and keep
  you in touch with the rapidly changing
  pharmaceutical markets, and make the best
  decisions for your business.

6
Table of Content

• Introduction 13
• Executive Summary 13
• Scope of the Report 14
• Antibody-Drug Conjugate Introduction 15
• Historical Perspective of Antibody-Drug
  Conjugate 15
• Design of Antibody-Drug Conjugate 17
• Different components of Antibody-Drug Conjugate
  17
• ImmunocongugateA distinct class of therapeutics
  in Oncology 20
• Advantages of ADC over Traditional Therapies 21
• Important Hurdles Faced in Development and
  Commercialization of ADC 22

7
List of Tables

• Table 1 Marketed and Pipeline Antibody-Drug
  Conjugates, 2015
• Table 2 Antibody-Drug Conjugate in Pipeline by
  Phase, 2015
• Table 3 Therapeutic Areas under Research for
  Antibody-Drug Conjugate Products, 2015
• Table 4 Number of Companies Targeting Different
  Therapeutics Areas in Antibody-Drug Conjugate
  Market Globally, 2015
• Table 5 Number of Companies Targeting Different
  Therapeutics Areas in Antibody-Drug Conjugate
  Market Globally, 2015
• Table 6 Number of Technologies with Companies
  for Antibody-Drug Conjugate Products Development,
  2015
• Table 7 Number of Companies Technology for
  Antibody-Drug Conjugates Development, 2015
• Table 8 Number of Companies with Monoclonal
  Antibodies for Antibody-Drug Conjugates
  Development, 2015

8
List of Figures

• Figure 1 Marketed and Pipeline Antibody-Drug
  Conjugates, 2015
• Figure 2 Phase III Antibody-Drug Conjugates and
  Trials, 2015
• Figure 3 Comparison Graph for Discovery and
  Pre-clinical Antibody-Drug Conjugates, 2015
• Figure 4 Antibody-Drug Conjugate in Pipeline by
  Phase, 2015
• Figure 5 Therapeutic Areas under Research for
  Antibody-Drug Conjugate Products, 2015
• Figure 6 Total Number of Companies Targeting
  Different Therapeutics Areas in Antibody-Drug
  Conjugate Market Globally, 2015
• Figure 7 Number of Companies Targeting
  Different Therapeutics Areas in Antibody-Drug
  Conjugate Market Globally, 2015
• Figure 8 Number of Technologies with Companies
  for Antibody-Drug Conjugate Products Development,
  2015
• Figure 9 Number of Companies with Technology
  for Antibody-Drug Conjugates Development, 2015

9
Related reports

• HER-2 Positive Breast Cancer Market in the US
  2015-2019
• Global Small Cell Lung Cancer Therapeutics Market
  2015-2019
• Global Osteoarthritis Market 2015-2019
• Global Laboratory Information Management System
  (LIMS) Market 2015-2019
• Global In-vitro Fertilization (IVF) Devices
  Market 2015-2019
• Global Acute Coronary Syndrome (ACS) Market
  2015-2019
• Global Automated External Defibrillator Market
  2015-2019
• Global Gaucher Disease Market 2015-2019
• Global In-vitro Fertilization (IVF) Devices
  Market 2015-2019
• Global Laboratory Information Management System
  (LIMS) Market 2015-2019

10

• Antibody Drug Conjugate Insight Pipeline
  Assessment, Technology Trend, and Competitive
  Landscape, 2015
• Published Mar 2015 342 Pages
• Antibody-Drug Conjugate Global Market and
  Pipeline Outlook, 2015, report provides the
  information across the ADCs drug value chain.
• Price

Formatss Price
PDF 3500
Site License 7000
Enterprise Wide License 10500
11
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news